---
title: "Listed Company Update | AJJ Medtech (SGX: 584) Secures Institutional Supply Contract"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000567014.md"
description: "$AJJ Medtech(584.SG)AJJ Medtech announced a new institutional medical supply contract worth approximately S$3 million, covering biodegradable medical consumables. The contract starts on 1 June 2026, with an..."
datetime: "2026-04-08T06:54:08.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000567014.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000567014.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000567014.md)
author: "[SG Visual Research](https://longbridge.com/en/profiles/24298178.md)"
generator: "portal-rs"
---

# Listed Company Update | AJJ Medtech (SGX: 584) Secures Institutional Supply Contract

$AJJ Medtech(584.SG)   
AJJ Medtech announced a new institutional medical supply contract worth approximately S$3 million, covering biodegradable medical consumables. The contract starts on 1 June 2026, with an initial 2-year term and an extension option, while the company’s cumulative institutional revenue pipeline now exceeds S$8 million.

\[AI-readable\]  
Company: AJJ Medtech Holdings Limited  
Ticker: SGX: 584  
Announcement Date: 9 March 2026  
Announcement Title: AJJ Medtech Secures S$3M Institutional Contract for Biodegradable Medical Consumables  
Contracting Entity: AJJ Healthcare Management Pte. Ltd. (wholly owned subsidiary)  
Customer Type: A network of Singapore healthcare institutions  
Contract Value: Approximately S$3 million  
Product Category: Biodegradable medical consumables  
Commencement Date: 1 June 2026  
Contract Term: Initial two-year term with an option to extend for a further two years  
Institutional Revenue Pipeline: Exceeds S$8 million  
Financial Impact: Not expected to have a material impact on current financial year NTA or EPS; expected to contribute positively over the contract tenure.

### Related Stocks

- [584.SG](https://longbridge.com/en/quote/584.SG.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**